MedTrace Logo

Arsenic Trioxide and Dexamethasone in Treating Patients With Recurrent or Refractory Stage II or Stage III Multiple Myeloma

NCT00017069 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2020-10-05

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.

PURPOSE: Phase II trial to study the effectiveness of combining arsenic trioxide and dexamethasone in treating patients who have recurrent or refractory stage II or stage III multiple myeloma.

Conditions

  • Multiple Myeloma and Plasma Cell Neoplasm

Interventions

DRUG

arsenic trioxide

DRUG

dexamethasone

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • CTI BioPharma

    lead INDUSTRY

Principal Investigators

  • Scott C. Stromatt, MD · CTI BioPharma

Study Design

Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-02-28
Primary Completion
2005-01-31
Completion
2005-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00017069 on ClinicalTrials.gov